TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion January 3, 1992
TCL Archive Zinder Report Implementation, Surgical Conference, On NCAB Meeting June 17-18 May 31, 1974
